Head to head
Sanofi vs Eli Lilly and Co
Side-by-side on the measures that matter, with a plain-English read. Full detail: SNY · LLY
SNY
Sanofi
40.20+1.62%
1-year price shape — -14% over the period
Quant Rating D · 23/100
vs
LLY
Eli Lilly and Co
1,188.72+2.70%
1-year price shape — +42% over the period
Quant Rating B · 79/100
1-year performance, rebased to 100
Eli Lilly and Co edges it on the scoreable measures. Eli Lilly and Co has the highest Quant Rating (79); Eli Lilly and Co has done best over the past year (+42%); Eli Lilly and Co earns the most per share.
| SNY | LLY | |
|---|---|---|
| Snapshot | ||
| Sector | Drug Manufacturers - General | Drug Manufacturers - General |
| Last price | 40.20 | 1,188.72 |
| Change today | +1.62% | +2.70% |
| 1-year return | -13.8% | +41.8% |
| Market cap | $96.32B | $1.12T |
| 52-week range | 39.18 – 49.91 | 778.93 – 1,292.65 |
| Valuation | ||
| P/E (TTM) | 21.97 | 39.90 |
| P/E percentile, own 5-yr range | 77th | 6th |
| P/B | 1.24 | 33.03 |
| Dividend yield | 5.88% | 0.54% |
| Profitability & growth | ||
| EPS (TTM) | 3.57 | 22.95 |
| Net profit (TTM) | $8.54B | $21.60B |
| Revenue (TTM) | $48.92B | $79.67B |
| Revenue growth (YoY) | +14.6% | +47.7% |
| Gross margin | 72.8% | 83.4% |
| Operating margin | 20.6% | 49.7% |
| Net margin | 8.1% | 33.5% |
| Free cash flow (TTM) | $7.00B | $13.56B |
| Ownership & sentiment | ||
| Institutional ownership | 53.0% | 79.5% |
| Insider activity (12mo) | 0 buy / 0 sell | 37 buy / 13 sell |
| Short interest (% of float) | 0.4% | 0.8% |
| Analyst consensus | 100% hold (3) | 91% buy / 5% hold / 5% sell (22) |
| Analyst price target | $53 (+32%) | $1,381 (+16%) |
| StockVane view | ||
| StockVane Quant Rating | D (23) | B (79) |
| Company | ||
| Employees | 74,846 | 50,000 |
| Founded | 1994 | 1876 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.